Literature DB >> 29396131

Donor PNPLA3 rs738409 genotype is a risk factor for graft steatosis. A post-transplant biopsy-based study.

Pavel Trunečka1, Irena Míková2, Dana Dlouhá3, Jaroslav A Hubáček3, Eva Honsová4, Libor Kolesár5, Věra Lánská6, Soňa Fraňková2, Jan Šperl2, Milan Jirsa3, Rudolf Poledne3.   

Abstract

BACKGROUND & AIMS: The rs738409 c.444C > G (p.I148M) polymorphism in PNPLA3 is a major factor predisposing to non-alcoholic fatty liver disease. The aim of the study was to clarify the impact of liver and extrahepatic expression of the PNPLA3 p.148M variant on liver graft steatosis after liver transplantation.
METHODS: Fat content was assessed in liver biopsies from 176 transplant recipients. During a period of 4 ± 1 years after transplantation, 17 patients developed grade 3 steatosis, 14 patients grade 2 steatosis, 56 patients grade 1 steatosis, and 89 patients grade 0 steatosis. The influence of the recipient and donor rs738409 genotype and clinical and laboratory data on liver fat content were analyzed using ordinal logistic regression.
RESULTS: The PNPLA3 rs738409 CC/CG/GG genotype frequencies, respectively, were 0.494/0.449/0.057 in the graft donors and 0.545/0.330/0.125 in the graft recipients. In the multivariate analysis, the presence of the PNPLA3 c.444G allele in donor (OR 1.62; 95%CI 1.12-2.33), post-transplant BMI (OR 1.14; 95%CI 1.07-1.22), diabetes mellitus (OR 1.99; 95%CI 1.22-3.22), and serum triglycerides (OR 1.40; 95%CI 1.11-1.76) were independent risk factors for increased liver graft fat content.
CONCLUSIONS: These data indicate that the liver expression of the PNPLA3 p.148M variant confers a genetic predisposition to liver graft steatosis along with nutritional status and diabetes.
Copyright © 2018 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Liver biopsy; Liver transplantation; NAFLD; PNPLA3

Mesh:

Substances:

Year:  2018        PMID: 29396131     DOI: 10.1016/j.dld.2017.12.030

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  12 in total

Review 1.  Pathogenesis of non-alcoholic fatty liver disease and implications on cardiovascular outcomes in liver transplantation.

Authors:  Benedict J Maliakkal
Journal:  Transl Gastroenterol Hepatol       Date:  2020-07-05

2.  Liver transplantation in the era of non-alcoholic fatty liver disease/metabolic (dysfunction) associated fatty liver disease: the dilemma of the steatotic liver graft on transplantation and recipient survival.

Authors:  Seren M Gedallovich; Daniela P Ladner; Lisa B VanWagner
Journal:  Hepatobiliary Surg Nutr       Date:  2022-06       Impact factor: 8.265

Review 3.  Extrahepatic organs in the development of non-alcoholic fatty liver disease in liver transplant patients.

Authors:  Renyi Su; Xuyong Wei; Qiang Wei; Di Lu; Zuyuan Lin; Shuo Wang; Chuxiao Shao; Xiao Xu
Journal:  Hepatobiliary Surg Nutr       Date:  2022-06       Impact factor: 8.265

Review 4.  Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges.

Authors:  Naga Swetha Samji; Rajanshu Verma; Krishna Chaitanya Keri; Ashwani K Singal; Aijaz Ahmed; Mary Rinella; David Bernstein; Manal F Abdelmalek; Sanjaya K Satapathy
Journal:  Dig Dis Sci       Date:  2019-07-16       Impact factor: 3.199

Review 5.  Importance of genetic polymorphisms in liver transplantation outcomes.

Authors:  Tomislav Kelava; Petra Turcic; Antonio Markotic; Ana Ostojic; Dino Sisl; Anna Mrzljak
Journal:  World J Gastroenterol       Date:  2020-03-28       Impact factor: 5.742

6.  Serum miR-33a is associated with steatosis and inflammation in patients with non-alcoholic fatty liver disease after liver transplantation.

Authors:  Denisa Erhartova; Monika Cahova; Helena Dankova; Marie Heczkova; Irena Mikova; Eva Sticova; Julius Spicak; Ondrej Seda; Pavel Trunecka
Journal:  PLoS One       Date:  2019-11-08       Impact factor: 3.240

7.  Clinical and Genetic Risk Factors of Recurrent Nonalcoholic Fatty Liver Disease After Liver Transplantation.

Authors:  Sanjaya K Satapathy; Quynh T Tran; Alexander J Kovalic; Sai Vineela Bontha; Yu Jiang; Satish Kedia; Saradashri Karri; Vamsee Mupparaju; Pradeep S B Podila; Rajanshu Verma; Daniel Maluf; Valeria Mas; Satheesh Nair; James D Eason; Dave Bridges; David E Kleiner
Journal:  Clin Transl Gastroenterol       Date:  2021-02-05       Impact factor: 4.488

Review 8.  Genetic and Life Style Risk Factors for Recurrent Non-alcoholic Fatty Liver Disease Following Liver Transplantation.

Authors:  Speranta Iacob; Susanne Beckebaum; Razvan Iacob; Cristian Gheorghe; Vito Cicinnati; Irinel Popescu; Liana Gheorghe
Journal:  Front Nutr       Date:  2022-01-14

9.  PNPLA3 and TM6SF2 genetic variants and hepatic fibrosis and cirrhosis in Pakistani chronic hepatitis C patients: a genetic association study.

Authors:  Bisma Rauff; Ali Amar; Badr Alzahrani; Shafiq A Chudhary; Bilal Nasir; Saqib Mahmood; Munir Ahmad Bhinder; Muhammad Faheem
Journal:  BMC Gastroenterol       Date:  2022-08-26       Impact factor: 2.847

10.  PNPLA3 rs738409 G allele carriers with genotype 1b HCV cirrhosis have lower viral load but develop liver failure at younger age.

Authors:  Renata Senkerikova; Sona Frankova; Milan Jirsa; Miluse Kreidlova; Dusan Merta; Magdalena Neroldova; Klara Chmelova; Julius Spicak; Jan Sperl
Journal:  PLoS One       Date:  2019-09-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.